AbbVie (ABBV) Stock Forecast, Price & News

AbbVie (NYSE:ABBV) Frequently Asked Questions

Is AbbVie a buy right now?

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 5 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AbbVie stock.
View analyst ratings for AbbVie or view top-rated stocks.

When is AbbVie's next earnings date?

AbbVie is scheduled to release its next quarterly earnings announcement on Friday, July 29th 2022.
View our earnings forecast for AbbVie.

How were AbbVie's earnings last quarter?

AbbVie Inc. (NYSE:ABBV) posted its quarterly earnings results on Friday, April, 29th. The company reported $3.16 EPS for the quarter, beating the consensus estimate of $3.14 by $0.02. The firm had revenue of $13.36 billion for the quarter, compared to the consensus estimate of $13.61 billion. AbbVie had a trailing twelve-month return on equity of 159.31% and a net margin of 22.00%. The company's revenue was up 2.7% on a year-over-year basis. During the same quarter last year, the business earned $2.95 EPS.
View AbbVie's earnings history.

How often does AbbVie pay dividends? What is the dividend yield for AbbVie?

AbbVie declared a quarterly dividend on Thursday, February 17th. Stockholders of record on Friday, April 15th will be given a dividend of $1.41 per share on Monday, May 16th. This represents a $5.64 dividend on an annualized basis and a yield of 3.73%. The ex-dividend date of this dividend is Wednesday, April 13th.
View AbbVie's dividend history.

Is AbbVie a good dividend stock?

AbbVie pays an annual dividend of $5.64 per share and currently has a dividend yield of 3.72%. AbbVie has been increasing its dividend for 50 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of AbbVie is 80.92%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, AbbVie will have a dividend payout ratio of 47.76% next year. This indicates that AbbVie will be able to sustain or increase its dividend.
View AbbVie's dividend history.

What guidance has AbbVie issued on next quarter's earnings?

AbbVie updated its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share (EPS) guidance of $13.92-$14.12 for the period, compared to the consensus estimate of $14.11. The company issued revenue guidance of $59.40 billion-$59.40 billion, compared to the consensus revenue estimate of $60.04 billion.

What price target have analysts set for ABBV?

16 analysts have issued 1 year price targets for AbbVie's stock. Their forecasts range from $135.00 to $200.00. On average, they expect AbbVie's stock price to reach $159.44 in the next twelve months. This suggests a possible upside of 5.6% from the stock's current price.
View analysts' price targets for AbbVie or view top-rated stocks among Wall Street analysts.

Who are AbbVie's key executives?

AbbVie's management team includes the following people:

• Mr. Richard A. Gonzalez, Chairman & CEO (Age 68, Pay $7.42M) (LinkedIn Profile)
• Dr. Michael E. Severino M.D., Vice Chairman & Pres (Age 56, Pay $4.29M) (LinkedIn Profile)
• Mr. Robert A. Michael, Vice Chairman of Fin. & Commercial Operations and CFO (Age 52, Pay $3.82M) (LinkedIn Profile)
• Ms. Laura J. Schumacher, Vice Chairman of External Affairs, Chief Legal Officer & Corp. Sec. (Age 59, Pay $4.18M) (LinkedIn Profile)
• Mr. Jeffrey Ryan Stewart, Exec. VP & Chief Commercial Officer (Age 53, Pay $3.25M)
• Dr. Azita Saleki-Gerhardt Ph.D., Exec. VP of Operations (Age 59)
• Dr. Thomas J. Hudson, Sr. VP of R&D and Chief Scientific Officer (Age 60)
• Ms. Elizabeth Shea, VP of Investor Relations
• Mr. Timothy J. Richmond, Exec. VP & Chief HR Officer (Age 56) (LinkedIn Profile)
• Mr. Henry O. Gosebruch, Exec. VP & Chief Strategy Officer (Age 49) (LinkedIn Profile)

What is Richard A. Gonzalez's approval rating as AbbVie's CEO?

580 employees have rated AbbVie CEO Richard A. Gonzalez on Glassdoor.com. Richard A. Gonzalez has an approval rating of 88% among AbbVie's employees.

Who are some of AbbVie's key competitors?

Some companies that are related to AbbVie include Johnson & Johnson (JNJ), Pfizer (PFE), Eli Lilly and (LLY), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Pacira BioSciences (PCRX), Corcept Therapeutics (CORT), Supernus Pharmaceuticals (SUPN), Nektar Therapeutics (NKTR) and Omeros (OMER).
View all of ABBV's competitors.

What other stocks do shareholders of AbbVie own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AbbVie investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), Vermilion Energy (VET), AT&T (T), Bristol-Myers Squibb (BMY), Wheaton Precious Metals (WPM), Rogers Communications (RCI) and Open Text (OTEX).

What is AbbVie's stock symbol?

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

Who are AbbVie's major shareholders?

AbbVie's stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.52%), BlackRock Inc. (7.34%), State Street Corp (4.42%), Capital International Investors (1.73%), Northern Trust Corp (1.28%) and Bank of New York Mellon Corp (1.12%). Company insiders that own AbbVie stock include Brian L Durkin, Carlos Alban, Carrie C Strom, Carrie C Strom, Elaine K Sorg, Henry O Gosebruch, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Richard A Gonzalez, Robert A Michael, Roxanne S Austin and Timothy J Richmond.
View institutional ownership trends for AbbVie.

Which major investors are selling AbbVie stock?

ABBV stock was sold by a variety of institutional investors in the last quarter, including Nomura Holdings Inc., Bank of New York Mellon Corp, State Street Corp, Federated Hermes Inc., abrdn plc, Renaissance Technologies LLC, UBS Group AG, and Capital Research Global Investors. Company insiders that have sold AbbVie company stock in the last year include Brian L Durkin, Carrie C Strom, Elaine K Sorg, Henry O Gosebruch, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Richard A Gonzalez, Robert A Michael, Roxanne S Austin, and Timothy J Richmond.
View insider buying and selling activity for AbbVie or view top insider-selling stocks.

Which major investors are buying AbbVie stock?

ABBV stock was acquired by a variety of institutional investors in the last quarter, including Capital International Investors, Vanguard Group Inc., Arrowstreet Capital Limited Partnership, California Public Employees Retirement System, BlackRock Inc., Swiss National Bank, Robeco Institutional Asset Management B.V., and Caisse DE Depot ET Placement DU Quebec.
View insider buying and selling activity for AbbVie or or view top insider-buying stocks.

How do I buy shares of AbbVie?

Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AbbVie's stock price today?

One share of ABBV stock can currently be purchased for approximately $151.01.

How much money does AbbVie make?

AbbVie has a market capitalization of $266.85 billion and generates $56.20 billion in revenue each year. The company earns $11.54 billion in net income (profit) each year or $6.97 on an earnings per share basis.

How many employees does AbbVie have?

AbbVie employs 50,000 workers across the globe.

Does AbbVie have any subsidiaries?

The following companies are subsidiares of AbbVie: AbbVie (Gibraltar) Holdings Limited, AbbVie (Gibraltar) Holdings Limited Luxembourg S.C.S., AbbVie (Gibraltar) Limited, AbbVie (Pty) Ltd., AbbVie A/S, AbbVie AB, AbbVie AG, AbbVie AS, AbbVie Australasia Holdings Limited, AbbVie B.V., AbbVie Bahamas Ltd., AbbVie Biofarmacevtska družba d.o.o., AbbVie Biopharmaceuticals GmbH, AbbVie Biopharmaceuticals LLC, AbbVie Biopharmaceuticals Ltd., AbbVie Bioresearch Center Inc., AbbVie Biotech Ventures Inc., AbbVie Biotechnology GmbH, AbbVie Biotechnology Ltd, AbbVie Biotherapeutics Inc., AbbVie Biotherapeutics Limited, AbbVie Central Finance B.V., AbbVie Corp, AbbVie Corporation, AbbVie Deutschland GmbH & Co. KG, AbbVie EOOD, AbbVie Endocrine Inc., AbbVie Endocrinology Inc., AbbVie Farmacéuticos S.A. de C.V., AbbVie Farmacêutica Ltda., AbbVie Finance B.V., AbbVie Finance Corporation, AbbVie Finance LLC, AbbVie GK, AbbVie GmbH, AbbVie Holdings Corporation, AbbVie Holdings Inc., AbbVie Holdings KK, AbbVie Holdings SAS, AbbVie Holdings Unlimited, AbbVie Holdings s.r.o., AbbVie International S.à r.l., AbbVie Investments Limited, AbbVie Investments S.à r.l., AbbVie Ireland Holdings Limited, AbbVie Ireland NL B.V., AbbVie Ireland Unlimited Company, AbbVie Japan Holdings B.V., AbbVie Kft., AbbVie Komplementär GmbH, AbbVie L.L.C., AbbVie L.da, AbbVie Limited, AbbVie Limited Liability Company, AbbVie Logistics B.V., AbbVie Ltd, AbbVie Ltd., AbbVie Manufacturing Management Limited, AbbVie Nederland Holdings B.V., AbbVie Operations Singapore Pte. Ltd., AbbVie Overseas S.à r.l., AbbVie Oy, AbbVie Participações Ltda., AbbVie Pharmaceutical Trading (Shanghai) Co. Ltd., AbbVie Pharmaceuticals B.V., AbbVie Pharmaceuticals GmbH, AbbVie Pharmaceuticals LLC, AbbVie Pharmaceuticals SCA., AbbVie Pharmaceuticals Societe Anonyme, AbbVie Polska Sp. z o.o., AbbVie Productos Farmacéuticos Limitada, AbbVie Products LLC, AbbVie Promoção L.da, AbbVie Pte. Ltd., AbbVie Pty Ltd, AbbVie Purchasing LLC, AbbVie Real Estate Management GmbH, AbbVie Research B.V., AbbVie Resources Inc., AbbVie Resources International Inc., AbbVie Respiratory LLC, AbbVie S. de R.L., AbbVie S.A., AbbVie S.A., AbbVie S.A.S., AbbVie S.R.L., AbbVie S.r.l., AbbVie S.à r.l., AbbVie SA, AbbVie SAS, AbbVie SIA, AbbVie Sarl, AbbVie Sdn. Bhd., AbbVie Sp. z o.o., AbbVie Spain S.L., AbbVie Stemcentrx LLC, AbbVie Trading S.R.L., AbbVie Trustee Company Limited, AbbVie Tıbbi İlaçlar Sanayi ve Ticaret Limited Şirketi, AbbVie UAB, AbbVie UK Biopharmaceuticals Ltd, AbbVie UK Holdco Limited, AbbVie UK Ltd, AbbVie US Holdings LLC, AbbVie US LLC, AbbVie Venezuela B.V., AbbVie Venezuela Holdings B.V., AbbVie Ventures LLC, AbbVie d.o.o., AbbVie s.r.o., Aeropharm Technology LLC, Allergan, BioDisplay Technologies Inc., Fournier Laboratories Ireland Ltd., Fremont Holding L.L.C., Fundación AbbVie, IEP Pharmaceutical Devices LLC, ImmuVen, KOS Pharmaceuticals Inc., Knoll LLC, Knoll Pharmaceutical Company, Life Properties Inc., Mavupharma, Organics L.L.C., Pharmacyclics (Europe) Limited, Pharmacyclics (Shanghai) Management Consulting Services Limited, Pharmacyclics Cayman Ltd., Pharmacyclics Inc, Pharmacyclics LLC, Pharmacyclics Switzerland GmbH, Rowell Laboratories Inc., S.C. AbbVie S.R.L., Sapphire Merger Sub Inc., Stem CentRx, Stemcentrx Cayman Ltd., Suffolk Merger Sub Inc., and Unimed Pharmaceuticals LLC.

When was AbbVie founded?

AbbVie was founded in 2013.

What is AbbVie's official website?

The official website for AbbVie is www.abbvie.com.

How can I contact AbbVie?

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at (847) 932-7900 or via fax at 302-655-5049.